Table 3 VEGF in vitreous and serum as DR progresses
Author, Year | Scale | Assay | Control (n) | T2DM | |||
|---|---|---|---|---|---|---|---|
NDR (n) | NPDR (n) | PDR (n) | |||||
Vitreous | Kaviarasan et al., 2015 [40] | ICDRDSS | ELISA for VEGF, PEDF, BDNF & LXA4; CBA for other cytokines | 33.78 ± 29.24 (18) | NA | NA | 971.75 ± 951.03a (27) |
Zhou et al., 2012 [58] | NA | ELISA | 16.57 ± 15.04 (20) | NA | NA | 1571.58 ± 957.68 (62) | |
Serum | Kaviarasan et al., 2015 [40] | ICDRDSS | ELISA for VEGF, PEDF, BDNF & LXA4; CBA for other cytokines | 960.09 ± 876.6 (27) | 660.41 ± 446.25 (27) | 590.16 ± 422.26 (30) | 960.09 ± 876.6 (30) |
Koleva-Georgieva et al., 2011 [48] | ETDRS | ELISA | 195.21 ± 128.53 (38) | 185.89 ± 141.95 (11) | 181.07 ± 117.92 (17) | 487.56 ± 225.20 (11) | |
Chorostowska-Wynimko et al., 2005 [45] | Ophthalmologist | ELISA | 375 ± 27.71 (12) | NA | 449 ± 176.67 (12) | NA | |
Nalini et al., 2017 [51] | Ophthalmologist | Immunoturbidimetry for CRP; ELISA for TNF-α and VEGF | 77.38 ± 12.23 (50) | 84.91 ± 14.78 (50) | 90.27 ± 14.92 (50) | 106.74 ± 8.91 (50) | |
Lee et al., 2008 [49] | ETDRS | chemiluminescent immunometric assay | NA | 86.41 ± 75.77 (28) | 59.43 ± 40.72 (39) | 102.88 ± 87.3 (7) | |
Ozturk et al., 2009 [53] | ICDRDSS | Luminex | 100.47 ± 49.66 (28) | 137.29 ± 84.45 (31) | 177.07 ± 119.51 (49) | 169.88 ± 109.12 (46) | |